John T. Catlow

1.4k citations

16 papers · 674 indexed · h-index 11

Cellular and Molecular Neuroscience top 5%
Molecular Biology
Psychiatry and Mental health top 5%
Pharmacology top 10%
Biological Psychiatry top 5%

Co-authors: Todd A. Gillespie S. P. Swanson Steven P. Swanson Steven Wrighton Mitchell A. Hamman Barbara J. Ring Benito J. Cerimele Lorin Roskos
Topics: Neuroscience and Neuropharmacology Research (9 papers)Receptor Mechanisms and Signaling (5 papers)Neurotransmitter Receptor Influence on Behavior (4 papers)
Cited by: Biological Psychiatry Cellular and Molecular Neuroscience Psychiatry and Mental health
Journals: Journal of Medicinal Chemistry Journal of Pharmacology and Experimental Therapeutics Neuropharmacology
Partner nations: United States United Kingdom

In The Last Decade

John T. Catlow

15 papers receiving 650 citations

Peers

Countries citing papers authored by John T. Catlow

Since Specialization

Citations

This map shows the geographic impact of John T. Catlow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John T. Catlow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John T. Catlow more than expected).

Fields of papers citing papers by John T. Catlow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John T. Catlow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John T. Catlow. The network helps show where John T. Catlow may publish in the future.

Co-authorship network of co-authors of John T. Catlow

This figure shows the co-authorship network connecting the top 25 collaborators of John T. Catlow. A scholar is included among the top collaborators of John T. Catlow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John T. Catlow. John T. Catlow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Expansion of Knowledge on OCT1 Variant Activity In Vitro and In Vivo Using Oct1/2−/− Mice 2021 ·Frontiers in Pharmacology ·Bridget L. Morse,(unknown),John T. Catlow,John K. Fallon,Philip C. Smith,Kathleen M. Hillgren	0
2	Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice 2017 ·CNS & Neurological Disorders - Drug Targets ·Anna Martin,Douglas A. Schober,Alexander Nikolayev,Vladimir Tolstikov,Wesley H. Anderson,Richard E. Higgs,Ming‐Shang Kuo,(unknown),John T. Catlow,Xia Li,Christian C. Felder,Jeffrey M. Witkin	29
3	Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611) 2017 ·CNS & Neurological Disorders - Drug Targets ·Jeffrey M. Witkin,Douglas A. Schober,Scott D. Gleason,John T. Catlow,Warren J. Porter,Jon K. Reel,Xiaoming Jin,(unknown),Donald R. Gehlert,Douglas L. Gernert,Kevin M. Gardinier,Akihiko Kato,Xingjie Ping,Jodi L. Smith	10
4	Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache 2016 ·Bioorganic & Medicinal Chemistry Letters ·María‐Jesús Blanco,(unknown),(unknown),Albert Khilevich,Guillermo S. Cortez,(unknown),Thomas D. Aicher,(unknown),(unknown),Tony P. Tang,Kirk W. Johnson,(unknown),Mark Muhlhauser,Steven Swanson,John T. Catlow,Renee Emkey,Michael P. Johnson,Jeffrey M. Schkeryantz	5
5	In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu 2/3 receptor antagonist 2015 ·Neuropharmacology ·Jeffrey M. Witkin,Paul L. Ornstein,Charles H. Mitch,Renhua Li,(unknown),Beverly A. Heinz,(unknown),Chuanxi Xiang,(unknown),Wesley H. Anderson,Xia Li,Lisa M. Broad,Francesca Pasqui,Stephen M. Fitzjohn,Helen Sanger,Jodi L. Smith,John T. Catlow,Steven Swanson,James A. Monn	18
6	M1 and M2 Muscarinic Receptor Subtypes Regulate Antidepressant-Like Effects of the Rapidly Acting Antidepressant Scopolamine 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Jeffrey M. Witkin,C. Overshiner,(unknown),John T. Catlow,Graham N. Wishart,Douglas A. Schober,B.A. Heinz,Alexander Nikolayev,Vladimir Tolstikov,Wesley H. Anderson,Richard E. Higgs,Ming‐Shang Kuo,Christian C. Felder	88
7	Further Evaluation of the Neuropharmacological Determinants of the Antidepressant-Like Effects of Curcumin 2013 ·CNS & Neurological Disorders - Drug Targets ·Jeffrey M. Witkin,(unknown),Linda Thompson,(unknown),Chunjin Ding,Beverly A. Heinz,John T. Catlow,Scott D. Gleason,Xia Li	14
8	Synthesis and Pharmacological Characterization of 4-Substituted-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: Identification of New Potent and Selective Metabotropic Glutamate 2/3 Receptor Agonists 2013 ·Journal of Medicinal Chemistry ·James A. Monn,Matthew J. Valli,Steven M. Massey,Junliang Hao,(unknown),Mark G. Bures,Beverly A. Heinz,Xushan Wang,(unknown),(unknown),Gregory A. Stephenson,Marc Hérin,John T. Catlow,Steven Swanson,Bryan G. Johnson,David L. McKinzie,Steven S. Henry	15
9	The 5-Hydroxytryptamine2A Receptor Antagonist R-(+)-α-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) Attenuates Impulsivity after Both Drug-Induced Disruption (Dizocilpine) and Enhancement (Antidepressant Drugs) of Differential-Reinforcement-of-Low-Rate 72-s Behavior in the Rat 2008 ·Journal of Pharmacology and Experimental Therapeutics ·Paul Ardayfio,Mark J. Benvenga,(unknown),Patrick L. Love,John T. Catlow,Steven P. Swanson,Gerard J. Marek	20
10	Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (–)-(1 R,4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039) 2007 ·Journal of Pharmacology and Experimental Therapeutics ·Linda M. Rorick‐Kehn,Bryan G. Johnson,Jennifer Burkey,Rebecca A. Wright,David O. Calligaro,Gerard J. Marek,Eric S. Nisenbaum,John T. Catlow,Ann E. Kingston,Deborah D. Giera,Marc Hérin,James A. Monn,David L. McKinzie,Darryle D. Schoepp	77
11	Synthesis and Metabotropic Glutamate Receptor Activity of S-Oxidized Variants of (−)-4-Amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: Identification of Potent, Selective, and Orally Bioavailable Agonists for mGlu2/3 Receptors 2006 ·Journal of Medicinal Chemistry ·James A. Monn,Steven M. Massey,Matthew J. Valli,Steven S. Henry,Gregory A. Stephenson,Mark G. Bures,Marc Hérin,John T. Catlow,Deborah D. Giera,Rebecca A. Wright,Bryan G. Johnson,Sherri L. Andis,Ann E. Kingston,Darryle D. Schoepp	51
12	Potent and Selective 1,2,3-Trisubstituted Indole NPY Y-1 Antagonists 1997 ·Journal of Medicinal Chemistry ·Philip A. Hipskind,Karen L. Lobb,James A. Nixon,Thomas C. Britton,Robert F. Bruns,John T. Catlow,(unknown),Susan L. Gackenheimer,Bruce D. Gitter,Smriti Iyengar,Douglas A. Schober,Rosa Maria A. Simmons,S. P. Swanson,Hamideh Zarrinmayeh,Dennis M. Zimmerman,Donald R. Gehlert	73
13	Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. 1996 ·Journal of Pharmacology and Experimental Therapeutics ·Barbara J. Ring,John T. Catlow,Thomas J. Lindsay,Todd A. Gillespie,Lorin Roskos,Benito J. Cerimele,S. P. Swanson,Mitchell A. Hamman,Steven Wrighton	170
14	Disposition of the opioid antagonist, LY255582, in rats and dogs. 1995 ·Drug Metabolism and Disposition ·Steven P. Swanson,John T. Catlow,Ralf Pöhland,(unknown),Timothy P. Johnson	7
15	Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection 1995 ·Journal of Chromatography B Biomedical Sciences and Applications ·John T. Catlow,(unknown),(unknown),Todd A. Gillespie,Michael Goodwin,Steven P. Swanson	95
16	Disposition of the novel serotonin agonist, LY228729, in monkeys and rats. 1992 ·Drug Metabolism and Disposition ·Steven P. Swanson,John T. Catlow	2

About John T. Catlow

John T. Catlow is a scholar working on Biological Psychiatry, Cellular and Molecular Neuroscience and Pharmacology, having authored 16 papers that have together received 674 indexed citations. Recurring topics across this work include Neuroscience and Neuropharmacology Research (9 papers), Receptor Mechanisms and Signaling (5 papers) and Neurotransmitter Receptor Influence on Behavior (4 papers). The work is most often cited by research in Biological Psychiatry (105 citations), Cellular and Molecular Neuroscience (315 citations) and Psychiatry and Mental health (194 citations). John T. Catlow has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Todd A. Gillespie, S. P. Swanson, Steven P. Swanson, Steven Wrighton, Mitchell A. Hamman, Barbara J. Ring, Benito J. Cerimele, Lorin Roskos, Thomas J. Lindsay and Michael Goodwin. Their work appears in journals such as Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and Neuropharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact